scholarly journals Polymeric piezoresistive airflow sensor to monitor respiratory patterns

2021 ◽  
Vol 18 (185) ◽  
Author(s):  
Sajad Abolpour Moshizi ◽  
Abolfazl Abedi ◽  
Majid Sanaeepur ◽  
Christopher J. Pastras ◽  
Zhao Jun Han ◽  
...  
Keyword(s):  
Graphene Nanosheets ◽  
High Sensitivity ◽  
Simulation Models ◽  
Sleep Apnoea ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease ◽  
Essential Information ◽  
Detection Range ◽  
Human Respiration ◽  
Airflow Sensor

Monitoring human respiratory patterns is of great importance as it gives essential information for various medical conditions, e.g. sleep apnoea syndrome and chronic obstructive pulmonary disease and asthma, etc. Herein, we have developed a polymeric airflow sensor based on nanocomposites of vertically grown graphene nanosheets (VGNs) with polydimethylsiloxane (PDMS) and explored their applications in monitoring human respiration. The sensing performance of the VGNs/PDMS nanocomposite was characterized by exposing to a range of airflow rates (20–130 l min −1 ), and a linear performance with high sensitivity and low response time (mostly below 1 s) was observed. To evaluate the experimental results, finite-element simulation models were developed in the COMSOL Multiphysics package. The piezoresistive properties of VGNs/PDMS thin film and fluid–solid interaction were thoroughly studied. Laser Doppler vibrometry measures of sensor tip displacement closely approximated simulated deflection results and validated the dynamic response of the sensor. By comparing the proposed sensor and some other airflow sensors in the literature, it is concluded that the VGNs/PDMS airflow sensor has excellent features in terms of sensor height, detection range and sensitivity. The potential application of the VGNs/PDMS airflow sensor in detecting the respiration pattern of human exercises like walking, jogging and running has been demonstrated.

scholarly journals Imaging in alpha-1 antitrypsin deficiency: a window into the disease

2021 ◽  
Vol 12_suppl ◽  
pp. 204062232110245
Author(s):  
Yuh-Chin Tony Huang ◽  
Marion Wencker ◽  
Bastiaan Driehuys
Keyword(s):  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease ◽  
Essential Information ◽  
Plain Chest Radiograph ◽  
Antitrypsin Deficiency ◽  
Alpha 1 Antitrypsin Deficiency ◽  
History Of ◽  
Detailed Assessment ◽  
Alpha 1 Antitrypsin ◽  
Magnetic Resonance Imaging Mri

Imaging modalities such as plain chest radiograph and computed tomography (CT) are important tools in the assessment of patients with chronic obstructive pulmonary disease (COPD) of any etiology. These methods facilitate differential diagnoses and the assessment of individual lung pathologies, such as the presence of emphysema, bullae, or fibrosis. However, as emphysema is the core pathological consequence in the lungs of patients with alpha-1 antitrypsin deficiency (AATD), and because AATD is associated with the development of other lung pathologies such as bronchiectasis, there is a greater need for patients with AATD than those with non-AATD-related COPD to undergo more detailed assessment using CT. In the field of AATD, CT provides essential information regarding the presence, distribution, and morphology of emphysema. In addition, it offers the option to quantify the extent of emphysema. These data have implications for treatment decisions such as initiation of alpha-1 antitrypsin (AAT) therapy, or suitability for surgical or endoscopic interventions for reducing lung volume. Furthermore, CT has provided vital insight regarding the natural history of emphysema progression in AATD, and CT densitometry has underpinned research into the efficacy of AAT therapy. Moving forward, hyperpolarized xenon gas (129Xe) lung magnetic resonance imaging (MRI) is emerging as a promising complement to CT by adding comprehensive measures of regional lung function. It also avoids the main disadvantage of CT: the associated radiation. This chapter provides an overview of technological aspects of imaging in AATD, as well as its role in the management of patients and clinical research. In addition, perspectives on the future potential role of lung MRI in AATD are outlined.

Respiratory medicine

2020 ◽  
pp. 263-310
Author(s):  
Chantal Simon ◽  
Hazel Everitt ◽  
Françoise van Dorp ◽  
Nazia Hussain ◽  
Emma Nash ◽  
...  
Keyword(s):  
General Practice ◽  
Lung Disease ◽  
Asthma Management ◽  
Sleep Apnoea ◽  
Respiratory Medicine ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease ◽  
Occupational Lung Disease ◽  
Obstructive Sleep ◽  
Diffuse Parenchymal Lung Disease

This chapter in the Oxford Handbook of General Practice explores respiratory medicine in general practice. It covers breathlessness, cough, chest signs, and other signs of respiratory disease. It examines asthma in adults, bronchodilators and steroids, asthma management in practice, and drug treatment of asthma, as well as chronic obstructive pulmonary disease (COPD) and acute exacerbations of COPD. It discusses lung cancer, colds and influenza, pneumonia, tuberculosis, cystic fibrosis and Kartagener syndrome, diffuse parenchymal lung disease, occupational lung disease, and snoring and obstructive sleep apnoea.

Atrial fibrillation and sleep apnoea and chronic obstructive pulmonary disease

ESC CardioMed ◽  
2018 ◽  
pp. 2235-2237
Author(s):  
Tauseef Akhtar ◽  
Jared D. Miller ◽  
Hugh Calkins
Keyword(s):  
Atrial Fibrillation ◽  
Chronic Obstructive Pulmonary Disease ◽  
Pulmonary Disease ◽  
Obstructive Sleep Apnoea ◽  
Sleep Apnoea ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease ◽  
Risk Factor Modification ◽  
Obstructive Sleep ◽  
P Rate

Rate control, rhythm control, and anticoagulation are well entrenched as the three central pillars of atrial fibrillation (AF) management. Risk factor modification of other associated co-morbidities is now emerging as a critical fourth pillar in the prevention and management of AF. Obstructive sleep apnoea and chronic obstructive pulmonary disease, in particular, have important implications in the development of AF and appropriate selection of therapy. This chapter reviews the pathophysiology and clinical evidence linking these conditions with AF. In addition, it discusses important considerations in the management of concurrent AF and obstructive sleep apnoea or chronic obstructive pulmonary disease.

Atrial fibrillation and sleep apnoea and chronic obstructive pulmonary disease

ESC CardioMed ◽  
2018 ◽  
pp. 2235-2237
Author(s):  
Jared D. Miller ◽  
Hugh G. Calkins
Keyword(s):  
Atrial Fibrillation ◽  
Chronic Obstructive Pulmonary Disease ◽  
Pulmonary Disease ◽  
Obstructive Sleep Apnoea ◽  
Sleep Apnoea ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease ◽  
Risk Factor Modification ◽  
Obstructive Sleep ◽  
P Rate

Rate control, rhythm control, and anticoagulation are well entrenched as the three central pillars of atrial fibrillation (AF) management. Risk factor modification of other associated co-morbidities is now emerging as a critical fourth pillar in the prevention and management of AF. Obstructive sleep apnoea and chronic obstructive pulmonary disease, in particular, have important implications in the development of AF and appropriate selection of therapy. This chapter reviews the pathophysiology and clinical evidence linking these conditions with AF. In addition, it discusses important considerations in the management of concurrent AF and obstructive sleep apnoea or chronic obstructive pulmonary disease.

Respiratory diseases and respiratory failure

2016 ◽  
Author(s):  
Professor Ann B Millar ◽  
Dr Richard Leach ◽  
Dr Rebecca Preston ◽  
Dr Richard Leach ◽  
Dr Richard Leach ◽  
...  
Keyword(s):  
Respiratory Failure ◽  
Lung Disease ◽  
Respiratory Diseases ◽  
Immunocompromised Host ◽  
Mycobacterial Infection ◽  
Sleep Apnoea ◽  
Disease Assessment ◽  
Chronic Obstructive ◽  
Diffuse Lung Disease ◽  
Obstructive Pulmonary Disease

Chapter 5 covers respiratory diseases and respiratory failure, including clinical presentations of respiratory disease, assessment of diffuse lung disease, hypoxaemia, respiratory failure, and oxygen therapy, pneumonia, mycobacterial infection, asthma, chronic obstructive pulmonary disease (COPD), lung cancer, mediastinal lesions, pneumothorax, pleural disease, asbestos-related lung disease, diffuse parenchymal (interstitial) lung disease, sarcoidosis, pulmonary hypertension, acute respiratory distress syndrome, bronchiectasis and cystic fibrosis, bronchiolitis, eosinophilic lung disease, airways obstruction, aspiration syndromes, and near-drowning, pulmonary vasculitis, the immunocompromised host, sleep apnoea, and rare pulmonary diseases.

Sign in / Sign up

Export Citation Format

Share Document